CN103200822B - 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用 - Google Patents

2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用 Download PDF

Info

Publication number
CN103200822B
CN103200822B CN201180038325.3A CN201180038325A CN103200822B CN 103200822 B CN103200822 B CN 103200822B CN 201180038325 A CN201180038325 A CN 201180038325A CN 103200822 B CN103200822 B CN 103200822B
Authority
CN
China
Prior art keywords
compound
pyrimidine
oxo
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180038325.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103200822A (zh
Inventor
E·P·雷迪
M·V·R·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of CN103200822A publication Critical patent/CN103200822A/zh
Application granted granted Critical
Publication of CN103200822B publication Critical patent/CN103200822B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180038325.3A 2010-08-05 2011-07-21 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用 Active CN103200822B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37094610P 2010-08-05 2010-08-05
US61/370,946 2010-08-05
PCT/US2011/044807 WO2012018540A1 (en) 2010-08-05 2011-07-21 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof

Publications (2)

Publication Number Publication Date
CN103200822A CN103200822A (zh) 2013-07-10
CN103200822B true CN103200822B (zh) 2014-12-24

Family

ID=45559737

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180038325.3A Active CN103200822B (zh) 2010-08-05 2011-07-21 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用

Country Status (17)

Country Link
US (1) US8987267B2 (enExample)
EP (1) EP2600719B1 (enExample)
JP (1) JP5512894B2 (enExample)
KR (1) KR101434841B1 (enExample)
CN (1) CN103200822B (enExample)
AU (1) AU2011286282B2 (enExample)
BR (1) BR112013002375B1 (enExample)
CA (1) CA2807498C (enExample)
DK (1) DK2600719T3 (enExample)
EA (1) EA022527B1 (enExample)
ES (1) ES2525866T3 (enExample)
IL (1) IL224555A (enExample)
MX (1) MX2013001427A (enExample)
NZ (1) NZ606281A (enExample)
PL (1) PL2600719T3 (enExample)
PT (1) PT2600719E (enExample)
WO (1) WO2012018540A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013002375B1 (pt) * 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
EP3733184B1 (en) 2013-03-14 2023-08-30 Icahn School of Medicine at Mount Sinai Pyrimidine compounds for use in the treatment of cancer
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CN104447739B (zh) * 2014-11-07 2016-02-17 郑州泰基鸿诺药物科技有限公司 一种氘代Palbociclib衍生物、制备方法及应用
CN104496983B (zh) 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
CN104447743B (zh) * 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
CN104478874B (zh) * 2014-12-08 2016-03-02 新发药业有限公司 一种帕博赛布的制备方法
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CN105111205B (zh) * 2015-09-12 2017-01-04 山东罗欣药业集团股份有限公司 一种帕博西尼的制备方法
JP7044801B2 (ja) 2016-12-16 2022-03-30 シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッド Ｃｄｋ４／６阻害剤
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
KR102286701B1 (ko) * 2018-09-28 2021-08-06 재단법인 대구경북첨단의료산업진흥재단 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
US20220002293A1 (en) * 2018-11-12 2022-01-06 Onconova Therapeutics, Inc. 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders
TWI818930B (zh) * 2018-11-12 2023-10-21 美商昂可諾法治療股份有限公司 8-環戊基-7-側氧基-2-(4-哌嗪-1-基-苯基胺基)-7,8-二氫-吡啶[2,3-d]嘧啶-6-氰基及其用於治療增生性疾病的用途
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
AU2019413683B2 (en) * 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN114340634A (zh) * 2019-07-02 2022-04-12 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
US20230132667A1 (en) * 2020-05-28 2023-05-04 University Of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
JP2024542205A (ja) * 2021-11-18 2024-11-13 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
EP4433060A1 (en) * 2021-11-18 2024-09-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2023230288A1 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
EP4618992A1 (en) * 2022-11-17 2025-09-24 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302301A (zh) * 1998-05-26 2001-07-04 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4－二氢嘧啶化合物
US20010027196A1 (en) * 2000-02-25 2001-10-04 Borroni Edilio Maurizio Adenosine receptor ligands and their use in the treatment of disease
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CN1422268A (zh) * 2000-03-06 2003-06-04 沃尼尔·朗伯公司 5－烷基吡啶并[2,3－d]嘧啶酪氨酸激酶抑制剂
CN1433417A (zh) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
US20080004285A1 (en) * 2004-12-30 2008-01-03 De Jonghe Steven C A Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20090062274A1 (en) * 2005-10-07 2009-03-05 Exelixis, Inc Pyridopyrimidinone inhibitors of pi3kalpha

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JP4291696B2 (ja) 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
RU2007128961A (ru) * 2004-12-30 2009-02-10 4 Аза Ип Ив (Be) ПИРИДО(3,2-d)ПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ПОЛЕЗНЫЕ ДЛЯ КОНСЕРВАТИВНОГО ЛЕЧЕНИЯ
EP1899332A1 (en) * 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
US20090191193A1 (en) 2006-08-02 2009-07-30 Temple University-Of The Commonwealth System Of Higher Education Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
EP2084159A1 (en) 2006-10-16 2009-08-05 GPC Biotech Inc. Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors
WO2008150260A1 (en) 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
BR112013002375B1 (pt) * 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CN1302301A (zh) * 1998-05-26 2001-07-04 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4－二氢嘧啶化合物
CN1433417A (zh) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
US20010027196A1 (en) * 2000-02-25 2001-10-04 Borroni Edilio Maurizio Adenosine receptor ligands and their use in the treatment of disease
CN1422268A (zh) * 2000-03-06 2003-06-04 沃尼尔·朗伯公司 5－烷基吡啶并[2,3－d]嘧啶酪氨酸激酶抑制剂
US20080004285A1 (en) * 2004-12-30 2008-01-03 De Jonghe Steven C A Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20090062274A1 (en) * 2005-10-07 2009-03-05 Exelixis, Inc Pyridopyrimidinone inhibitors of pi3kalpha

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
synthesis and reactivity of 2,6-diamino-4-methyl-3-pyridinecabonitrile;Alan R.Katritzky etal;《Journal of heterocyclic chemistry》;19951231;第32卷(第3期);第1-18页，参见第第15页图解1 *

Also Published As

Publication number Publication date
DK2600719T3 (da) 2014-12-15
US8987267B2 (en) 2015-03-24
US20130131058A1 (en) 2013-05-23
EP2600719B1 (en) 2014-10-08
EA022527B1 (ru) 2016-01-29
CA2807498A1 (en) 2012-02-09
EP2600719A1 (en) 2013-06-12
CN103200822A (zh) 2013-07-10
IL224555A (en) 2016-03-31
KR101434841B1 (ko) 2014-08-29
PL2600719T3 (pl) 2015-03-31
EP2600719A4 (en) 2014-01-01
PT2600719E (pt) 2014-12-22
EA201390199A1 (ru) 2013-07-30
AU2011286282B2 (en) 2014-08-21
NZ606281A (en) 2014-09-26
JP5512894B2 (ja) 2014-06-04
KR20130098314A (ko) 2013-09-04
WO2012018540A1 (en) 2012-02-09
BR112013002375A2 (pt) 2016-05-24
JP2013538196A (ja) 2013-10-10
MX2013001427A (es) 2013-06-13
BR112013002375B1 (pt) 2020-05-12
CA2807498C (en) 2017-02-07
AU2011286282A1 (en) 2013-02-14
ES2525866T3 (es) 2014-12-30

Similar Documents

Publication Publication Date Title
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
ES2904544T3 (es) Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos
WO2023284537A1 (en) Kras g12d inhibitors and uses thereof
CN104995184B (zh) 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物
US20240368184A1 (en) PIKfyve Inhibitors
AU2015335783B2 (en) Tricyclic atropisomer compounds
AU2011377440A1 (en) Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
ES2660215T3 (es) Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina
CN108456163A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
CN101218238A (zh) 咪唑并[1,2-a]吡啶衍生物：制备及药学应用
CN111247152A (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
WO2016192131A1 (zh) 激酶抑制剂及其应用
JP5797664B2 (ja) 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
TW201300390A (zh) 喹□啉化合物
CN103664734B (zh) 杂环羟肟酸类化合物及其药用组合物和应用
CN106957303A (zh) 选择性AuroraA激酶抑制活性的喹唑啉衍生物及其制备方法以及应用
AU2010330863B2 (en) Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
WO2017181973A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
CN115403568A (zh) 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
WO2025247067A1 (zh) Kif18A抑制剂
WO2019149223A1 (zh) 苯甲酰胺类化合物及其制备方法、用途和药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant